Manufacturing and Marketing permission issued from SND Division from to

Similar documents
Manufacturing and Marketing permission issued from SND Division from to

Manufacturing and Marketing permission issued from SND Division from to

Manufacturing and Marketing permission issued from SND Division from to

Area Drug and Therapeutics Committee Prescribing Supplement No 59 July 2012

Drugs approved from 1st January 2015 till present. S.NO Name Of Drug Indication Date of Approval 1 Levocetirizine ODS 2.5mg /5mg (Additional

ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER

MEETING OF THE BORDERS FORMULARY COMMITTEE HELD ON WEDNESDAY, 8 TH AUGUST P.M. IN THE COMMITTEE ROOM, EDUCATION CENTRE

NB Drug Plans Formulary Update

Area Drug and Therapeutics Committee Prescribing Supplement No 55 March 2012

PUO in the Immunocompromised Host: CMV and beyond

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 08/19/14 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

REACH Risk Evaluation to Achieve Cardiovascular Health

Blood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen

eltrombopag (Promacta )

An Overview of Blood and Marrow Transplantation

Elements for a Public Summary

STATIN UTILIZATION MANAGEMENT CRITERIA

Medicine Condition being treated NHSGGC Decision Date of decision. 18 June 2018 Page 1 of 5

IMMUNE GLOBULIN (IVIG AND SCIG) Brand Name Generic Name Length of Authorization Bivigam IVIG Per Medical Guidelines Carimune IVIG Per Medical

29 August 2016 Page 1 of 7. How does the NHS board decide which new medicines to make available for patients?

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010

Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL

TRANSPARENCY COMMITTEE OPINION. 27 January 2010

Opinion 23 July 2014

2. Is therapy prescribed by, or in consultation with, a hematologist and/or oncologist?

See Important Reminder at the end of this policy for important regulatory and legal information.

Obinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.

NBPDP Formulary Update

Clinical Policy: Eltrombopag (Promacta) Reference Number: ERX.SPA.71 Effective Date:

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti-Cancer Treatment Protocol. Abiraterone. PROCTOCOL REF: MPHAABIRA (Version No: 1.

WARNING LETTER. The Indications and Usage section of the approved product labeling (PI) for Prograf states:

Promacta (eltrombopag)

Gazyva. Gazyva (obinutuzumab) Description

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

HMO: Medical (provider setting); Rx (out patient) PPO/CDHP: Rx

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010

Maintenance rituximab following response to first-line therapy in mantle cell lymphoma

See Important Reminder at the end of this policy for important regulatory and legal information.

Indolent Lymphomas: Current. Dr. Laurie Sehn

Indolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital

Rayos Prior Authorization Program Summary

Elements for a public summary

VI.2 Elements for a public summary

Area Drug and Therapeutics Committee Prescribing Supplement No 47 July 2011

Gazyva. Gazyva (obinutuzumab) Description

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Hot Topics: Transitions of Care

Elements for a Public Summary

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection

BR for previously untreated or relapsed CLL

Gazyva (obinutuzumab)

PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN BY PRODUCT

Pharmacy Prior Authorization

Subsequent New Drugs Division. M/s.Troikaa. M/s. Olive Healthcare. Biological Division. M/s. Wockhardt Ltd. Global Clinical Trial Division

Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL)

Abiraterone and Prednisolone Therapy

Product Visual Guide

Rituximab in Lymphoma and Chronic Lymphocytic Leukemia: A Clinical Practice Guideline, Version 3

RITUXAN (rituximab and hyaluronidase human)

Thrombopoietin Receptor Agonists Prior Authorization with Quantity Limit Program Summary

FUJI study: Follow-Up of Jevtana in real life

EASY AZITHROMYCIN 250 MG

disease or in clients who consume alcohol on a regular basis. bilirubin

Summary of the risk management plan (RMP) for Gazyvaro (obinutuzumab)

Recommendation:- The 19 th SEC - (Oncology & Hematology) deliberated the proposals on and recommended the following:-

EU PSUR Work Sharing Summary Assessment Report AFLAMIN (aceclofenac) HU/H/PSUR/0030/002 HU

PRODUCT MONOGRAPH. obinutuzumab. 25 mg/ml Concentrate for Solution for Infusion. Professed Standard. Antineoplastic

Antiemetic protocol for rare emetogenic chemotherapy - see protocol SCNAUSEA

Immunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

TRANSPARENCY COMMITTE OPINION. 19 December 2007

Corporate Medical Policy

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 5 January 2011

NEWS RELEASE Genentech Contacts: Media: Joe St. Martin (650) Investor: Karl Mahler Thomas Kudsk Larsen (973)

MANTLE CELL LYMPHOMA

PROMACTA (eltrombopag olamine) oral tablet and oral suspension

For peripheral blood stem cell (PBSC) mobilization prior to and during leukapheresis in cancer patients preparing to undergo bone marrow ablation

NCCP Chemotherapy Regimen. Obinutuzumab Maintenance Therapy following O-Bendamustine therapy

TRANSPARENCY COMMITTEE OPINION. 14 February 2007

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE)

BC Cancer Protocol Summary for the Treatment of rituximabrefractory Follicular Lymphoma (FL) with obinutuzumab in combination with Bendamustine

AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)

Pediatric Oncology. Vlad Radulescu, MD

Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division)

Contents Please refer to Medical Policy I-40 Pertuzumab (Perjeta) for additional information.

QUICK REFERENCE Clinical Practice Guideline on the Evaluation and Management of Immune Thrombocytopenia (ITP)

CLINICAL MEDICAL POLICY

UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma

Obinutuzumab in combination with bendamustine for treating rituximab-refractory follicular lymphoma

Antiallergics and drugs used in anaphylaxis

Expert Review: Updates in Immune Thrombocytopenia. Reference Slides

Velcade (bortezomib)

AXITAB-CV TAB. COMPOSITION :

Drug Class Prior Authorization Criteria Immune Globulins

Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand

Appendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014

LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center

Metformin Hydrochloride

Description of Commitment

Transcription:

Manufacturing and Marketing permission issued from SND Division from 01.01.2017 to 17.07.2017. S.No. Drug Name Indication Date of Approval 1 Sofosbuvir 400 film coated Tablet In combination with other medicinal products for the treatment of Chronic Hepatitis C (CHC) in adults 16.02.2017 2 Hydralazine tablets BP 25 (Additional Strength) 3 Hydralazine tablets BP 50 (Additional Strength) 4 Bendamustine hydrochloride injection 90 /ml (Fill volume 0.5 ml in 2 ml capacity vial & 2 ml filled in 2 ml capacity vial) 5 Eltrombopagolamine 25 /50 tablets 6 Azacitidine for injection 100 7 Methylcobalamin 1500 mcg orally disintegrating strips 8 Cefditoren Pivoxil dry powder for suspension 100 /5 ml For moderate to severe hypertension (in conjunction with a β-adrenoceptor blocking agent or diuretic) and hypertensive crisis. For moderate to severe hypertension (in conjunction with a β-adrenoceptor blocking agent or diuretic) and hypertensive crisis. 1. For the treatment of patients with chronic lymphocytic leukemia 2. For the use in Indolent B-cell Non- Hodgkin s Lymphoma (NHL) that has Progressed During or Within six months of treatment with Rituximab or a Rituximab containing Regimen. For the treatment of thrombocytopenia in paediatric patients 1 year and older with chronic immune(idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. (It should be used only in patients with ITP whose degree of Thrombocytopenia and clinical condition increase the risk for bleeding. It should not be used in an attempt to normalize platelet counts). For the treatment of adult patients with all subtypes of Myelodysplastic Syndrome For the treatment of Diabetic Neuropathy and peripheral Neuropathy For the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the condition listed below Acute Bacterial Exacerbation of Chronic Bronchitis Community-Acquired pneumonia Pharyngitis/Tonsillitis 23.02.2017 23.02.2017 02.03.2017 02.03.2017 07.03.2017 10.03.2017 30.03.2017

9 Thiotepa Powder for concentrate for solution for infusion 100 (Additional strength & indication) 10 Thiotepa Powder for concentrate for solution for infusion 15 11 Bortezomib for Injection (i.v) 1 /vial 12 Bortezomib 3.5 /vial Powder for solution for injection (i.v/s.c) 13 Mesalamine Delayed Release Tablets 800 (Additional dosage form) 14 Teneligliptin Film coated Tablet 20 15 Ticagrelor 60 tablets (Additional strength & indication) Acute sinusitis Uncomplicated skin and skin-structure infections. 1. With or without total body irradiation(tbi), as conditioning treatment prior to allogenic or autologous hematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and pediatrics patients; 2. When high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumors in adult and pediatrics patients. prescription of Hematologist only 1. With or without total body irradiation(tbi), as conditioning treatment prior to allogenic or autologous hematopoietic progenitor cell transplantation(hpct) in haematological disease in adult and pediatrics patients; 2. When high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumors in adult and pediatrics patients. prescription of Hematologist only For the treatment of patients with mantle cell lymphoma For the treatment of patients with mantle cell lymphoma For the treatment of mild to moderate acute exacerbations of ulcerative colitis and for the maintenance of remission of ulcerative colitis. prescription of Specialist/Gastroenterologist only For the treatment of Type 2 Diabetes Mellitus as a monotherapy adjunct to diet and exercise. Indicated for the prevention of thrombotic events (cardiovascular death, myocardial infarction and stroke) in patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing a thrombotic event. 06.04.2017 06.04.2017 11.04.2017 11.04.2017 11.04.2017 28.04.2017 02.05.2017

16 Daclatasvir Tablet 30 17 Daclatasvir Tablet 60 18 Rosuvastatin Tablets 15 19 Rosuvastatin film coated Tablets 30 prescription of Cardiologist/Internal Medicine Speciality only For use with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection. prescription of Hepatologist only For use with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection. prescription of Hepatologist only a. Treatment of patients with primary hypercholesterolemia or mixed dyslipedemia, homozygous familial hyper cholesterolemia as an adjutant to diet,when response to diet and excercise is inadequate b. As an adjunctive therapy to diet for the treatment of adult patients with hypertriglycerdemia. c. As an adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower total C and LDL-C to target levels. d. Risk reduction of Myocardial Infarction stroke and arterial revascularization procedure in patients without clinically evident CHD but with multiple risk factors. e. As an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (type-iii hyperlipoprotenemia). f. As adjunct to diet to reduce total- C,LDL-C and ApoB levels in adolescent boys and girls,who are atleast one year post-menarche,10-17 years of age with heterozygous familial hypercholesterolemia if after and adequate trial of diet therapy the following findings are present:ldl-c >190 /dl or > 160 /dl and there is a positive family history of premature cardiovascular disease (CVD) or two or more CVD risk factors. a. Treatment of patients with primary hyper cholesterolemia or mixed dyslipedemia, homozygous familial hyper cholesterolemia as an adjutant to diet,when response to diet and excercise is inadequate b. As an adjunctive therapy to diet for the 24.05.2017 24.05.2017 30.05.2017 30.05.2017

20 Abiraterone Acetate Tablet 500 21 Enzalutamide hard Gelatin Capsules 40 22 Rizatriptan Benzoate Strips 5 treatment of adult patients with hypertriglycerdemia. c. As an adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower total C and LDL-C to target levels. d. Risk reduction of Myocardial Infarction stroke and arterial revascularization procedure in patients without clinically evident CHD but with multiple risk factors. e. As an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (type-iii hyperlipoprotenemia). f. As adjunct to diet to reduce total-c, LDL-C and ApoB levels in adolescent boys and girls, who are atleast one year post-menarche,10-17 years of age with heterozygous familial hypercholesterolemia if after and adequate trial of diet therapy the following findings are present: LDL-C >190 /dl or > 160 /dl and there is a positive family history of premature cardiovascular disease (CVD) or two or more CVD risk factors. 1. In combination with prednisone for 12.07.2017 the treatment of patients with metastatic castration resistant prostate cancer who have received prior chemotherapy containing docetaxel 2. For the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated with prednisone or prednisolone. For the treatment of adults with metastatic 12.07.2017 castration resistant prostate cancer whose disease has progressed on or after Docetaxel therapy. Anti-Migraine 19.07.2017

23 Rizatriptan Benzoate Strips 10 24 Vitamin D3 (Cholecalciferol) 60000 IU Orally disintegrating Strips 25 Empagliflozin 10, 25 Tablet (Additional indication) Anti-Migraine 19.07.2017 For the treatment of Vitamin D3 deficiency 25.08.2017 To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease. 22.09.2017 26 Ketamine Injection 50/ml (5ml & 10ml vial) Veterinary use only 27 Tacrolimus Prolonged Release Hard Gelatin Capsules 3 28 Clonazepam IP Strips 0.5 29 Clonazepam IP Strips 1. Ketamine Injection may be used in cats for restraint or as the sole anesthetic agent for diagnostic or minor, brief, surgical procedures that do not require skeletal muscle relaxation. It may be used in subhuman primates for restraint. prescription of a Veterinary Doctor only 1. Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. 2. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients. Warning:-to be sold on the prescription of physicians experienced in immunosuppressive therapy and management of organ transplant only In the treatment of petitmal, its variant, akinetic & myoclonic seizures. prescription of a Neurologist & Psychiatrist only In the treatment of petitmal, its variant, akinetic & myoclonic seizures. prescription of a Neurologist & Psychiatrist only 03.10.2017 13.10.2017

30 Clonazepam IP Strips 2. In the treatment of petitmal, its variant, akinetic & myoclonic seizures. prescription of a Neurologist & Psychiatrist only 31 Diclofenac Diethylamine 2.32 % w/w Gel For the local symptomatic treatment of post-traumatic inflammation of the tendons, ligaments, muscles and joints. Localized forms of rheumatism & softtissue rheumatism. 32 Ibuprofen 100/ml Intravenous injection (8ml vial) 33 Crizotinib Hard Gelatin Capsules 200 (Additional indication) 34 Crizotinib Hard Gelatin Capsules 250 (Additional indication) 35 Progesterone Sustaied Release Tablet 200, 300, 400 (Micronised) Caldolor is an NSAID indicated in adults for the: 1. Management of mild to moderate pain. 2. Management of moderate to severe pain as an adjunct to opioid analgesics. 3. Reduction of fever. Crizotinib is a kinese inhibitor indicated for the treatment of patients with metastatic NSCLC whose tumors are ROS1-positive. prescription of a Oncologist only Crizotinib is a kinese inhibitor indicated for the treatment of patients with metastatic NSCLC whose tumors are ROS1-positive. prescription of a Oncologist only For the treatment of secondary amenorrhea associated with normal estrogen level in women 02.11.2017 03.11.2017 03.11.2017 03.11.2017